Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment
Authors:
- D.J. BrooksDBD.J. Brooks
- Y. AgidYAY. Agid
- K. EggertKEK. Eggert
- H. WidnerHWH. Widner
- K. ØstergaardKØK. Østergaard
- A. HolopainenAHA. Holopainen
- 1 July 2005
- journal article
- clinical trial
- Published by S. Karger AG in European Neurology
- Vol. 53 (4) , 197-202
Abstract
The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo® (levodopa, carbidopa and entacapone) in patients with Parkinson’s disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess®/Comtan®). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCI to either an equivalent dose of Stalevo or levodopa/DDCI plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson’s Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCI plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label studyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
- Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month studyJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Treatment interventions for Parkinson's disease: an evidence based assessmentThe Lancet, 2002
- An algorithm (decision tree) for the management of Parkinson’s disease (2001):Neurology, 2001
- Twelve‐month safety of entacapone in patients with Parkinson’s diseaseEuropean Journal of Neurology, 2001
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patientsAnnals of Neurology, 1997
- Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsNeurology, 1994
- Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's diseaseEuropean Journal of Clinical Pharmacology, 1993
- Clinical experience with controlled‐release carbidopa/levodopa in Parkinson's diseaseNeurology, 1993